Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarizotan for L-dopa-induced dyskinesia in Parkinson's
NCT00314288Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Jul 2002
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of sarizotan in dyskinesia, sponsored by EMD Serono. Primary endpoint: Change from baseline in diary-based 'on' time without dyskinesia. Started Jul 2002; status: completed.
02
Drugs
sarizotan
03
Conditions
dyskinesia
Beyond the preview
Go deeper on NCT00314288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00314288.